Athenex, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on May 14, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Athenex Pharmaceuticals LLC, Athenex Pharmaceutical Division, LLC, Athenex R&D LLC, Cell Medica, Inc. and Kuur Therapeutics Inc., with its own case for administrative and procedural purposes. Athenex, Inc. has been proposed as the lead debtor.